Exelixis (EXEL) Reports In-Line Q4 EPS, Slight Miss on Revenues

Exelixis (NASDAQ: EXEL) reported Q4 EPS of $0.12, in-line with the analyst estimate of $0.12. Revenue for the quarter came in at $120.1 million versus the consensus estimate of $120.25 million.

• Total Revenue of $120.1 million for the Fourth Quarter of 2017, $452.5 million for the Full Year 2017
• Cabozantinib Franchise Net Product Revenue of $95.7 million for the Fourth Quarter of 2017, $349.0 million for the Full Year 2017
• Diluted EPS of $0.12 per Share for the Fourth Quarter of 2017, $0.49 for the Full Year 2017

For earnings history and earnings-related data on Exelixis (EXEL) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Innovaro (INV) Misses Q2 EPS by 9c